Qiagen Reports Strong Asset Growth in Q3 2025

Qiagen ( (QGEN) ) has shared an update.

On November 5, 2025, Qiagen N.V. released its quarterly report for the period ending September 30, 2025, prepared under U.S. GAAP. The report highlights a significant increase in total assets, reaching $6.55 billion compared to $5.69 billion at the end of 2024. This growth is attributed to increases in cash and cash equivalents, goodwill, and property, plant, and equipment. The financial results reflect Qiagen’s strengthened market position and operational expansion, which may positively impact stakeholders by enhancing the company’s capacity to invest in innovation and market opportunities.

The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.

Spark’s Take on QGEN Stock

According to Spark, TipRanks’ AI Analyst, QGEN is a Neutral.

Qiagen’s overall stock score is driven by strong earnings call performance and stable financials. However, technical analysis indicates bearish momentum, and valuation metrics suggest potential overvaluation. The company’s strategic initiatives and growth plans provide a positive outlook, but challenges in profitability growth and cash flow conversion remain.

To see Spark’s full report on QGEN stock, click here.

More about Qiagen

Qiagen N.V. operates in the biotechnology industry, specializing in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on enabling customers to gain valuable insights from biological samples, which is crucial for advancing healthcare and life sciences.

Average Trading Volume: 1,236,450

Technical Sentiment Signal: Sell

Current Market Cap: $9.58B

For an in-depth examination of QGEN stock, go to TipRanks’ Overview page.